Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

For adults with moderate-to-severe AD, upadacitinib 30 mg appears to be the most efficacious treatment in attaining more stringent and ...

Upadacitinib 30 mg appears to be the most efficacious treatment in attaining more stringent and composite outcomes across multiple timepoints.

524 - Efficacy of upadacitinib and dupilumab on achieving stringent ...

For adults with moderate-to-severe AD, upadacitinib 30 mg appears to be the most efficacious treatment in attaining stringent and composite ...

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

Armstrong AW, Hong HC, Calimlim BM, Buessing MG, Crowell MM, Silverberg JI. Efficacy of Upadacitinib and Dupilumab on Achieving Stringent [.

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

At week 16, 248 patients receiving upadacitinib (72.4%) and 207 patients receiving dupilumab (62.6%) achieved EASI75 (P = .007). All ranked ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

At week 16, 248 patients receiving upadacitinib (72.4%) and 207 patients receiving dupilumab (62.6%) achieved EASI75 (P = .007). All ranked ...

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

The analysis was conducted on adult patients, aligned with the intention-to treat population for the clinical trials, and used non-responder ...

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

For adults with moderate-to-severe AD, upadacitinib 30 mg appears to be the most efficacious treatment in attaining more stringent and composite outcomes across ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Most patients who did not achieve adequate clinical responses with dupilumab did so with upadacitinib. The safety profile of upadacitinib up ...

524 - Efficacy of upadacitinib and dupilumab on achieving stringent ...

Conclusions For adults with moderate-to-severe AD, upadacitinib 30 mg appears to be the most efficacious treatment in attaining stringent and composite outcomes ...

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib ...

The co-primary endpoints were the percentage of patients achieving EASI 75 and a validated Investigator's Global Assessment for Atopic ...

Upadacitinib Demonstrates Efficacy in Patients With AD and Head ...

Overall, upadacitinib 15mg and upadacitinib 30mg outperformed placebo regarding a greater proportion of patients achieved a clinically ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

Superior efficacy in achieving simultaneous EASI 90 and WP-NRS 0/1 response at Week 16 was demonstrated with UPA vs DUPI (19.9% vs 8.9%, ...

Upadacitinib Outperforms Dupilumab in Primary and Secondary End ...

Upadacitinib demonstrated superior efficacy compared to dupilumab in the primary end point of the simultaneous achievement of a 90% or ...

Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for ...

Results: Greater proportions of patients treated with upadacitinib versus dupilumab achieved skin clearance rates of ≥75% (EASI 75) at week 1 ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol ...

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab ...

This study demonstrated that anti-JAK therapy, particularly abrocitinib and upadacitinib, exhibited superiority over dupilumab in achieving fast relief of ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Meaning This follow-up analysis of 2 randomized clinical trials found that continuous upadacitinib treatment showed a favorable longer-term ...

524 - Efficacy of upadacitinib and dupilumab on achieving stringent ...

524 - Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to- ...

Safety and efficacy of upadacitinib in combination with - BINASSS

A substantial proportion of patients achieved the stringent ... monoclonal antibody dupilumab achieve clear or almost clear skin ...